Author: [AUTHOR] Published on 10/1/2025 12:00:00 AM
Hongtao Yu, PhD, Clinical Pharmacometrician, AstraZeneca, Waltham, Massachusetts
What does being the Early Development & Drug Safety (EDDS) Community Vice Chair mean to you?
Serving as the EDDS Community Vice Chair is both an honor and a responsibility. It is a great opportunity to support shaping the conversation around innovative science in early drug development and safety, while fostering collaboration and professional growth within our community.
What is your favorite part of being the Early Development & Drug Safety (EDDS) Community Vice Chair?
My favorite part is working closely with an inspiring group of ASCPT members to advance the mission of the EDDS community. I enjoy facilitating connections between members from diverse backgrounds and helping to organize discussions bridging the gap between science, medicine, and patient outcomes.
What professional accomplishment are you most proud of?
I am most proud of my contributions to model-informed drug development, especially integrating quantitative pharmacology and clinical pharmacometrics to inform key decisions for early-stage therapeutics. Seeing my work directly impact drug development pipelines and patient safety has been especially rewarding.
How do you keep focused and motivated?
I stay motivated by seeing how model-informed drug development (MIDD) directly supports decision-making throughout the drug development process. While there may not always be immediate or explicit feedback from patients or the team, I find purpose in striving for impactful solutions – exploring different possibilities and working to turn challenges into opportunities for progress. Knowing that our efforts can help bring innovative therapies to patients keeps me focused and inspired.
Dr. Yu has been a member of ASCPT since 2025.
